自动化CT分析纵向预测特发性肺纤维化结局
本研究探讨计算机衍生的CT变量——血管相关结构变化——能否作为IPF试验的协同终点。该变化是IPF结局的强预测因子,与FVC变化联合使用可提高未来药物试验的检验效能,并有助于判定边缘性FVC下降。
要点
- 血管相关结构变化是IPF结局的强预测因子。
- 该CT变量与FVC变化联合作为协同终点可提高试验效能。
- 有助于区分边缘性FVC下降是测量变异还是真实恶化。
核心结论
- 血管相关结构变化是IPF结局的强预测因子。
- 该CT变量作为协同终点与FVC变化联合可提高未来药物试验的检验效能。
研究设计与样本
- 本研究分析系列CT检查中计算机特征(CALIPER)的变化。
- 研究关注该变化能否作为试验协同终点,尤其用于判定边缘性FVC下降。
主要发现
- 血管相关结构变化是IPF结局的强预测因子。
- 该变化与FVC变化联合作为协同终点可提高IPF药物试验的敏感性。
关键数值与推荐
- 年度化FVC下降在5.00%至9.99%之间时尤其难以解读,可能反映测量变异或真实临床恶化。
临床怎么用
- 在IPF药物试验中可考虑将血管相关结构变化与FVC变化联合作为协同终点。
- 该CT变量有助于判定边缘性FVC下降的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Change in the vessel-related structures, a computer-derived CT variable, is a strong predictor of outcome in idiopathic pulmonary fibrosis and can increase power in future drug trials when used as a co-endpoint alongside forced vital capacity change http://bit.ly/2M7DfKS The advent of antifibrotic agents [1, 2] as standard of care in idiopathic pulmonary fibrosis (IPF) requires that new non-inferiority IPF drug trials will need to identify smaller declines of forced vital capacity (FVC). Marginal annualised FVC declines (between 5.00 and 9.99%) are particularly challenging to interpret as they might reflect measurement variation or genuine clinical deterioration [3]. Following on from previous baseline-only computed tomography (CT) analyses [4], the current study examined whether changes in computer features (CALIPER) across serial CT examinations could be considered as a trial co-endpoint, particularly with regard to adjudicating marginal FVC declines, and therefore improve the sensitivity of IPF drug trials.
引用
- Jacob J, Bartholmai BJ, van Moorsel CHM, et al. Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. Eur Respir J. 2019. PMID: 31196945. doi:10.1183/13993003.02341-2018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。